Looking for abnormal, clumped features — dubbed mulberry bodies by scientists — in cells of a person’s urine may be…
Marisa Wexler, MS
Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Marisa Wexler, MS
ST-920 (isaralgagene civaparvovec), an experimental gene therapy for Fabry disease that’s currently headed toward Phase 3 clinical testing,…
In Fabry disease, a protein called alpha-synuclein forms clumps inside kidney cells, a toxic buildup that isn’t reversed by…
Freeline Therapeutics is pausing development of FLT190, an experimental gene therapy for Fabry disease. The move will…
The same mutation caused both late-onset and classic forms of Fabry disease among different members of the same family,…
Testing family members of people diagnosed with Fabry disease can identify new individuals with the condition and improve their…
The European Commission (EC) is expected to decide whether to approve PRX-102 (pegunigalsidase alfa) for adults with Fabry…
People with Fabry disease often have impairment in the nerves that help regulate heartbeat, which may serve as a…
More than one in 10 people with Fabry disease have a form of swelling called lymphedema, a recent study…
The U.S. Food and Drug Administration (FDA) has placed a hold on the 4D-310 clinical program, an experimental gene therapy…